Print Page      Close Window     

Events & Presentations

May 2019?
Calendar Help
This calendar contains six months of past and future company related information, which may include press releases, SEC filings, calendar events and more. Dates containing information are indicated by a colored background. Please select a highlighted date from the calendar to see date-specific company information, including a link to additional information. This calendar requires JavaScript to be installed and activated on your browser.
Calendar Icon Legend:
Analyst Meeting
Conference
Conference Presentation
Corporate Conference Call
Custom Events
Earnings Conference Call
Earnings Release
Financial Reports
Mergers & Acquisition Announcement
Guidance Announcement
Other Corporate
Sales Call/Presentation
Sales Release
Shareholders Meeting
News Release
SEC Filings
Presentations
52 Week High
Today
SMTWTFS
-3-2-11234
567891011
121314151617
05/17/19
4
Formats:  HTML Adobe PDF Word
4
Formats:  HTML Adobe PDF Word
4
Formats:  HTML Adobe PDF Word
4
Formats:  HTML Adobe PDF Word
4
Formats:  HTML Adobe PDF Word
4
Formats:  HTML Adobe PDF Word
18
19202122232425
26272829303151
Calendar Instructions
Please select a highlighted date from the calendar to view company related information. This calendar requires JavaScript to be installed and activated on your browser.
Upcoming Events
DateTitleRemind MePrior to Event
06/01/19 9:00 a.m. ET
Preliminary Results From CLASSICAL-Lung, a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
Supporting  
Materials:  
Download Event Supporting Material Preliminary Results From CLASSICAL-Lung, a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
days
06/03/19 2:15 p.m. ET
Pilot Integrated Biomarker Study of VX15/2503 in Combination with Ipilimumab and/or Nivolumab in Patients with Resectable Metastatic Melanoma
Supporting  
Materials:  
Download Event Supporting Material Pilot Integrated Biomarker Study of VX15/2503 in Combination with Ipilimumab and/or Nivolumab in Patients with Resectable Metastatic Melanoma
days
Enter your e-mail address 
Past Events
DateTitle
04/01/19 1:00 p.m. ET
Vaccinex, Inc. - Interim results from CLASSICAL-Lung, a Phase Ib/II study of VX15/2503 (pepinemab) in combination with avelumab in advanced NSCLC
Supporting 
Materials: 
Download Event Supporting Material Presentation
04/01/19 8:00 a.m. ET
Vaccinex, Inc. - Altered myeloid and lymphoid composition of tumor microenvironment following anti-SEMA4D and immune checkpoint combination therapies
Supporting 
Materials: 
Download Event Supporting Material Presentation
03/31/19 1:00 p.m. ET
Vaccinex, Inc. - Integrated biomarker trials of VX15/2503 (pepinemab) in combination with checkpoint inhibitors in window of opportunity studies in solid tumors
Supporting 
Materials: 
Download Event Supporting Material Presentation
03/19/19 3:55 p.m. ET
Vaccinex, Inc. at the Oppenheimer & Co.’s 29th Annual Healthcare Conference
03/12/19
Q4 2018 Vaccinex, Inc. Earnings Release
01/18/19
Vaccinex, Inc. at the PEPTALK: Advancing CNS Biotherapeutics and Crossing the Blood-Brain Barrier
Supporting 
Materials: 
Download Event Supporting Material PEPTALK: Advancing CNS Biotherapeutics and Crossing the Blood-Brain Barrier Presentation
11/16/18
Vaccinex, Inc. at the 2018 Huntington’s Study Group (HSG) Annual Meeting
Supporting 
Materials: 
Download Event Supporting Material Presentation at the 2018 Huntington’s Study Group (HSG) Annual Meeting
11/13/18
Q3 2018 Vaccinex, Inc. Earnings Release
11/09/18 through 11/10/18
Vaccinex, Inc. at the Annual Conference of the Society of Immunotherapy for Cancer
Supporting 
Materials: 
Download Event Supporting Material Podium Presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Download Event Supporting Material Poster at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
10/25/18
Vaccinex, Inc. at the BTIG Healthcare Conference
10/04/18
Vaccinex, Inc. at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
Supporting 
Materials: 
Download Event Supporting Material Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Presentation
Download Event Supporting Material Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Poster
10/02/18 8:30 a.m. ET
Vaccinex, Inc. at the Ladenburg Thalmann 4th Annual Healthcare Conference
09/30/18 11:45 a.m. ET
Vaccinex, Inc. at the International Cancer Immunotherapy Conference
Presentations
DateTitle
06/03/19
Pilot Integrated Biomarker Study of VX15/2503 in Combination with Ipilimumab and/or Nivolumab in Patients with Resectable Metastatic Melanoma
06/01/19
Preliminary Results From CLASSICAL-Lung, a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
04/29/19
Poster Presented on April 29, 2019 at AACR-AHNS Head and Neck Cancer Conference: “Integrated biomarker trials to evaluate myeloid and lymphoid composition of HNSCC and solid tumors treated with pepinemab and combinations with checkpoint inhibitors”
04/01/19
Interim results from CLASSICAL-Lung, a phase 1b/2 Study of VX15/2503 (pepinemab) in combination with avelumab in advanced NSCLC
04/01/19
Altered myeloid & lymphoid composition of tumor microenvironment following anti-SEMA4D and immunotherapies
04/01/19
Integrated biomarker trials of VX15/2503 (pepinemab) in combination with checkpoint inhibitors in window of opportunity studies in solid tumors
03/18/19
Corporate Presentation
01/18/19
PEPTALK: Advancing CNS Biotherapeutics and Crossing the Blood-Brain Barrier Presentation
11/16/18
Poster at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
11/16/18
Podium Presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
11/16/18
Presentation at the 2018 Huntington’s Study Group (HSG) Annual Meeting
10/04/18
Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Presentation
10/04/18
Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Poster